1. The necessity of developing cytokines in the Department of Hematology
In the treatment of some diseases, such as bloodstream infection, hemophagocytic syndrome (HLH), leukemia, sepsis, etc., the inflammatory response status of patients is mostly detected, so cytokine detection plays an important role in the selection, adjustment and prognosis evaluation of treatment regimens.
⇔Hemophagocytic syndrome
HLH is an immunodeficiency condition in which the ability to maintain immune balance is lost due to impaired immunity. As a result, HLH is a rapidly progressing, highly lethal disease, with a median survival of no more than 2 months in untreated patients. Cytokines are screening pathway items, and timely screening of cytokine concentrations can effectively avoid misdiagnosis and missed diagnosis.
⇔leukaemia
In the treatment of leukemia, chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in the field of relapsed and refractory B lymphocytic tumors, and more and more studies have begun to develop the application of CAR-T therapy in other types of tumors and diseases.
⇔Sepsis
For children with hematologic cancers, severe sepsis or septic shock can rapidly progress to organ dysfunction and even death during chemotherapy due to the strong effects of the drug leading to immune damage.
Cytokine screening was performed in patients at high risk of sepsis and patients suspected of systemic inflammatory response to determine the status of SIRS, and the pro-inflammatory factors mainly involved in SIRS include TNF-α, 1L-1, 1-6, and 1L-12p70; Anti-inflammatory cytokines include: IL-4, IL-10, IL-35, IL-37, TGF-β, IL-13, etc. Patients at high risk of sepsis infection should be monitored regularly (repeat every 2 to 4 hours).